一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括VS-7375，当前状态为招募中。登记地点显示中国Los Angeles、Atlanta、East Brunswick、New York等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
VS-7375 · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- START LA · Los Angeles
- Cedars-Sinai Medical Center · Los Angeles
- Valkyrie Clinical Trials · Los Angeles
- Emory Winship Cancer Institute · Atlanta
- START New Jersey · East Brunswick
- NYU · New York
- Memorial Sloan Kettering Cancer Center · New York
- START Fort Worth · Fort Worth
- MD Anderson Cancer Center · Houston
- University of Virginia · Charlottesville
- Chris O'Brien Lifehouse · Camperdown
- Macquarie University Hospital · Sydney
- ICON Cancer Centre South Brisbane · Brisbane
公开的入选条件
- * Histopathology confirmed unresectable locally advanced or metastatic NSCLC
- * Measurable disease per RECIST 1.1
- * Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
- * ECOG PS=0 or 1
- * Adequate organ function
- * Received prior treatment with a platinum-based chemotherapy regimen and an immune checkpoint inhibitor in the advanced, non-resectable setting.
- * Have documented disease progression during or following their most recent prior line of therapy.
- Patients with 2L/3L on stable or preferred dose:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07659782；登记信息更新于 2026-09-17。